Head-to-head · free

MiniMed Group, Inc. vs Merck

MMED vs MRK — return on capital, cash generation, margins and balance sheet side by side.

MMED

0 / 8

measures where MMED leads

MRK

8 / 8

measures where MRK leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureMMED · FY2026MRK · FY2025
Revenue$3.1B$65.0B
Net income(333.0M)$18.3B
Revenue growth (yearly, multi-year)—7.5%
Free cash flow(420.0M)$12.4B
Free cash flow margin-13.5%19.0%
Net cash / (debt)——
ROIC—19.0%
Return on equity-9.6%36.9%
Gross margin54.2%74.8%
Operating margin-5.1%34.0%
Net debt / EBITDA4.74x1.29x

Figures are as reported by each company; latest fiscal year shown.

Where MiniMed Group, Inc.'s cash went (FY2026)

Capital spending
$223.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MMED profile →

Where Merck's cash went (FY2025)

Capital spending
$4.1B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MRK profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons